We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
(+76%)
Cap. Flow
+$79.7M
Cap. Flow
% of AUM
14.07%
Top 10 Holdings %
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$10.7M |
| 2 |
Sanofi
SNY
|
+$9.45M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$9.01M |
| 4 |
Pennant Group
PNTG
|
+$8.5M |
| 5 |
MDCO
Medicines Co
MDCO
|
+$7.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$7.86M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$7.4M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$6.78M |
| 4 |
DexCom
DXCM
|
+$6.17M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$5.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.4% |
| 2 | Miscellaneous | 13.14% |
| 3 | Real Estate | 1.69% |
| 4 | Communication Services | 1.29% |
| 5 | Industrials | 0.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cytokinetics
CYTK
$10B
| $1.93M | 0.34% |
181,700
| – | – |
|
|
TLGT
52
DELISTED
Teligent, Inc
TLGT
| $1.92M | 0.34% |
450,180
+7,758
| +2% | +$48.2K |
|
53
Humana
HUM
$46.3B
| $1.84M | 0.32% |
+5,009
| New | +$1.59M |
|
|
SCPH
54
DELISTED
scPharmaceuticals
SCPH
| $1.71M | 0.3% |
301,636
+80,000
| +36% | +$409K |
|
55
Community Health Systems
CYH
$413M
| $1.68M | 0.3% |
580,364
-27,019
| -4% | -$93.6K |
|
56
Sabra Healthcare REIT
SBRA
$5.27B
| $1.62M | 0.29% |
76,054
-78,046
| -51% | -$1.75M |
|
|
MYOK
57
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $1.56M | 0.28% |
+21,452
| New | +$1.3M |
|
|
CARM
58
DELISTED
Carisma Therapeutics
CARM
| $1.35M | 0.24% |
+65,000
| New | +$1.49M |
|
59
InflaRx
IFRX
$329M
| $1.33M | 0.23% |
+334,618
| New | +$978K |
|
60
MacroGenics
MGNX
$263M
| $1.27M | 0.22% |
116,998
-37,826
| -24% | -$374K |
|
61
Immunovant
IMVT
$8.51B
| $1.22M | 0.22% |
+76,866
| New | +$861K |
|
62
Liquidia Corp
LQDA
$6.06B
| $1.21M | 0.21% |
+284,103
| New | +$1.14M |
|
|
EIGR
63
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.04M | 0.18% |
2,324
| – | – |
|
|
SPPI
64
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $1M | 0.18% |
+275,600
| New | +$2.23M |
|
|
OPTN
65
DELISTED
OptiNose
OPTN
| $968K | 0.17% |
7,000
-7
| -0.1% | -$908 |
|
|
PFNX
66
DELISTED
Pfenex Inc.
PFNX
| $508K | 0.09% |
46,293
-1,675
| -3% | -$16.6K |
|
|
FTSV
67
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $464K | 0.08% |
+11,795
| New | +$189K |
|
68
CALL
TG Therapeutics
TGTX
$8.26B
| $461K | 0.08% |
+41,500
| New | +$316K |
|
|
TARO
69
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $436K | 0.08% |
+4,953
| New | +$418K |
|
|
DRNA
70
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $411K | 0.07% |
18,674
-22,400
| -55% | -$451K |
|
|
RDUS
71
CALL
DELISTED
Radius Health, Inc.
RDUS
| $113K | 0.02% |
+5,600
| New | +$136K |
|
|
AKRX
72
DELISTED
Akorn Inc
AKRX
| $60.4K | 0.01% |
40,242
| – | – |
|
|
73
Alnylam Pharmaceuticals
ALNY
$31.7B
| – | – |
-92,040
| Closed | -$7.4M |
|
74
Codexis
CDXS
$174M
| – | – |
-63,000
| Closed | -$864K |
|
75
PUT
CEL-SCI Corp
CVM
$27.4M
| – | – |
-1,427
| Closed | -$383K |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.
On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.
- Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
- Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
- Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
- Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
- Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
- Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
- Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.
Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.